We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

EFFECTS OF PRESENCE OF OFF-LABEL-CRITERIA ON DOOR-TO-NEEDLE-TIME IN SYSTEMIC THROMBOLYSIS FOR ACUTE STROKE TREATMENT

Submitted

15 Views
1 Downloads
0 Saves

Presented at

ESOC-2019

-

Presentation

thumbnail

Abstract

Title: Effects of presence of off-label-criteria on door-to-needle-time in systemic thrombolysis for acute stroke treatment Background: Thrombolysis is the only approved pharmacological therapy for acute ischemic stroke. Several contraindications result from the stringent inclusion and exclusion criteria used in landmark RCTs. Nonetheless, off-label-treatment is common in acute stroke care. In previous studies most off-label criteria were not associated with higher risk of symptomatic intracerebral haemorrhage (SICH). Aim: To analyze, if presence of off-label-criteria influences door-to-needle time. Methods: We analyzed treatment protocols of all patients who received thrombolysis in the TEMPiS telestroke network between 01.01.2015 and 31.12.2017. Off-label criteria were defined according to the European licence of alteplase. Kruskal-Wallis test with Dunn’s post-hoc test and linear regression modelling with interaction terms were used for test of significance. Results: Of 2792 patients, 680 (24.4%) had at least one contraindication for thrombolysis (19.3% with one, 3.9%, 0.9%, 0.1% and 0.1% with 2-5 contraindications, respectively). Most common contraindications were history of prior stroke and concomitant diabetes (18.4%), elevated blood pressure (14.9%) and onset >4.5h or unknown (10.3%). Presence of at least one off-label-criterium led to significant delay of door-to-needle-time (47min vs. 41min; p<0.0001) with a tendency to longer delays with more contraindications. Difference was seen irrespective of whether thrombolysis was initiated via telemedicine or onsite (7min vs. 4min difference, p=0.36). Conclusion: Presence of off-label-criteria was associated with longer door-to-needle-time in patients treated with thrombolysis in the TEMPiS-network. Considering the potentially detrimental effect for patients and recently published data on SICH in off-label thrombolysis, further research evaluating the safety concerns underlying the alteplase licence criteria is needed.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.